These areas generally provide adequate skin surface area, relatively consistent drug absorption, and can be easily accessed for application while remaining concealed under clothing
In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost 22.5% of their body weight at 72 weeks compared to 2.4% in the placebo group
Maximum Fracture force analysis 3.3
Gastrointestinal adverse events such as diarrhea, nausea, vomiting, and decreased appetite were more common with tirzepatide than placebo or basal insulin but similar to GLP-1 receptor agonists [11]
Dizziness during the first dose or during dose increases usually lasts for a few minutes to a few hours
Diagnosing IBD in Cats Because IBD shares symptoms with other GI conditions, diagnosis typically involves multiple steps